Inotrem Announces Publication of Two Key Articles on Nangibotide Phase II Programs in Peer-reviewed Medical Journals
Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory conditions, announced today the publication of the results of two phase 2 clinical studies in the The Lancet Respiratory Medicine and in eClinicalMedicine. The first article presents the ASTONISH Phase 2b trial in septic shock patients and the second one the ESSENTIAL Phase 2 trial for the treatment of critically ill COVID-19 patients.Both studies reveal that the TREM-1 pathway plays a central role in major life-threatening immune dysregulations caused by severe infections, whether it is septic shock or severe forms of COVID-19. The findings presented further validate Inotrem’s innovative approach to treat inflammatory diseases by targeting TREM-1.
The two studies suggest that nangibotide, which targets TREM-1, is pathogen agnostic and has the potential to treat those very severe inflammatory conditions caused by both viral and bacterial infections. Both studies highlight the potential of nangibotide in the treatment of septic shock patients and of patients with severe forms of COVID-19 with a biomarker guided approach using soluble TREM-1 as predictive marker of response to targeted therapy.
The first manuscript in The Lancet Respiratory Medicine is entitled “Prospective evaluation of the efficacy, safety, and the optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock: a double-blind, randomized, controlled, phase 2b trial” and presents results from 355 septic shock patients. The primary outcome was the change in SOFA at day 5 compared to placebo in the pre-defined high soluble TREM-1 (≥ 400 pg/ml) group and in the overall population. Planned evaluation of the optimal sTREM-1 cut-off revealed increased clinically relevant benefits of high dose nangibotide at higher cutoffs (sTREM-1 ≥ 532 pg/ml). The manuscript can be accessed via the following link: The Lancet Respiratory Medicine.
The second manuscript in eClinicalMedicine, entitled “Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID19 receiving respiratory support: results of the ESSENTIAL randomized, double-blind trial” presents the Phase 2 results obtained in 220 COVID-19 patients receiving ventilatory support. In this study, nangibotide has a significant and positive impact on the clinical progression of the disease, as well as on the severity of the respiratory failure, secondary infection rates and notably mortality. The trial showed that sTREM-1 is an effective prognostic marker of outcome in severe COVID-19. The manuscript can be accessed via the following link: eClinicalMedicine.
“Nangibotide is the first TREM-1 inhibitor and has the potential to become the first causal treatment of life-threatening immune dysregulations. This is an area with a major unmet medical need” said Professor Bruno François, Limoges University Hospital, and lead author on the two manuscripts.
“We are excited to see this data published in The Lancet Respiratory Medicine and in eClinicalMedicine, two of the most established peer-reviewed medical journals in our field. These two publications come as a strong recognition of Inotrem’s innovative scientific leadership regarding the role of the TREM-1 pathway and of our solid therapeutic approaches” said Sven Zimmermann, CEO of Inotrem. “We look forward to bringing this potential new treatment option to patients suffering from severe and often fatal inflammatory conditions.”
Nangibotide is a TREM-1 inhibitor peptide with the potential to restore appropriate inflammatory response, vascular function, and improve post septic shock survival. Nangibotide is the formulation of the active ingredient LR12, which is a 12 amino-acid peptide prepared by chemical synthesis. LR12 is a specific TREM-1 inhibitor, acting as a decoy receptor and interfering in the binding of TREM-1 and its ligand. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals’ survival post septic shock. Nangibotide in septic shock has been granted the fast-track status in September 2019 by the FDA and the PRIME status in 2017 by the EMA.
About ASTONISH Study
The Efficacy, Safety and Tolerability of nangibotide in Patients with Septic Shock (ASTONISH) phase 2b trial is a Randomized, Double-blind, Placebo Controlled Dose Selection Study that was performed in Europe and in the US. The study compared the effect of nangibotide at two different doses (0.3 and 1mg/kg/h continuous i.v. infusion for 3 to 5 days) versus standard of care. Results for Phase IIb ASTONISH clinical trial in septic shock patients were disclosed for the first time at the International Sepsis Forum held in Barcelona on October 13. 2022.
About ESSENTIAL Study
The ESSENTIAL phase 2 trial is a double-blind randomized controlled trial assessing efficacy, safety, and optimum treatment population of nangibotide (1·0 mg/kg/h) compared to placebo. The study was stopped after 220 patients had been recruited; of them, 219 were included in the mITT analysis. Patients aged 18-75 years were eligible within 7 days of SARS-CoV-2 documentation and within 48 hours of onset invasive or non-invasive respiratory support because of COVID-19-related ARDS. ESSENTIAL data were disclosed for the first time at the ESICM meeting held in Paris in October 25. 2022.
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock, severe forms of COVID-19 and myocardial infarction. In parallel, Inotrem has also launched an antibody-based program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr Marc Derive. Inotrem is supported by leading European and North American investors Inotrem is part of the French Tech 120, a government program dedicated to support the development of fast-growing startups. www.inotrem.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Media contact for Inotrem
Strategies & Image (S&I)
+33 6 03 35 92 0
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KuCoin Breaks 30 Million Users as the Exchange Celebrates Its 6 th Anniversary25.9.2023 12:00:00 CEST | Press release
KuCoin, a top five cryptocurrency exchange in the world, is celebrating its 6th Anniversary with a breakthrough achievement of surpassing 30 million users, two momentous milestones of its journey at the same time. This remarkable achievement is a testament to KuCoin's commitment to excellence and its unwavering dedication to the global crypto community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230925301707/en/ KuCoin, a top five cryptocurrency exchange in the world, is celebrating its 6th Anniversary with a breakthrough achievement of surpassing 30 million users, two momentous milestones of its journey at the same time. To commemorate this celebration, KuCoin is rolling out the campaign "Rising Together: Celebrate 6th Anniversary of KuCoin with Million-Dollar Prize Pool", giving back to the community that has been integral to its success. (Graphic: Business Wire) Since its inception, KuCoin has been committed to provid
Aster Guardians Global Nursing Award 2024 is Now Open for Entry Worldwide, One Nurse Will Win the US $250,000 Award25.9.2023 11:42:00 CEST | Press release
In its continued efforts to recognize the contribution of nurses to humanity and the healthcare community, Aster DM Healthcare has announced the third edition of the Aster Guardians Global Nursing Award. The award invites registered nurses from across the world to apply by submitting nomination of their work on www.asterguardians.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230924862974/en/ Nurses can apply in one Primary and up to two Secondary areas of contribution, namely – Patient Care, Nursing Leadership, Nursing Education, Social or Community service and Research/ Innovation/ Entrepreneurship in Healthcare. The secondary areas of contribution can be optional. All applications received will follow a stringent review process led by an independent jury and an external advisory firm – Ernst & Young LLP (EY). The Grand Jury, consisting of an independent panel of renowned experts will review the shortlisted applicatio
Biosynth extends its offering to multi-kilogram GMP peptide synthesis through the acquisition of Pepceuticals25.9.2023 11:00:00 CEST | Press release
Biosynth, a supplier of critical materials to the life science industry, is pleased to announce the acquisition of Pepceuticals, a UK producer of synthetic peptides with multi-kilogram GMP facilities and fill-finish capabilities designed to support customers from clinical trials to commercial supply. Dr. Urs Spitz, CEO and President of Biosynth, commented, “We are very excited for Pepceuticals to be joining Biosynth. The Pepceuticals team has great expertise in optimizing the production of peptides and working at GMP and larger scales, making it a natural fit for Biosynth as we round out our peptide offering." Ehab Alramahy, Senior Vice President, Head of Peptide Division, added “The acquisition of Pepceuticals into the Biosynth family strengthens our position in the peptide field. As we've built the peptide division, our goal has always been to offer a seamless, comprehensive service to our customers. The acquisition represents an important step which allows us to extend our support t
Mercedes-Benz Teams up With Mastercard to Introduce Native In-Car Payments at the Pump: Pay by Fingerprint Directly in the Car With Mercedes pay+25.9.2023 09:00:00 CEST | Press release
Mercedes-Benz customers in Germany can now start the fueling process directly from their vehicle and pay digitally by fingerprint. Eliminating the need to enter a PIN or authenticate via mobile device, drivers can now leverage convenient payments to enhance the in-vehicle experience. The native in-car payment service via Mercedes pay+ will turn the car into a form of payment device and can be used to make payments at service stations using the fingerprint sensor integrated into the MBUX infotainment system. This is now live with Mastercard debit and credit cards in current Mercedes-Benz models.1 Fingerprint payment authorization at a gas station represents the first use case for native in-car payments at the point of sale, in addition to Mercedes-Benz as the world's first automaker to integrate Mastercard's Secure Card on File for Commerce platform into the car. This technology allows for transaction data to be encrypted using uniquely assigned cryptograms,2 in turn protecting sensitiv
Capcom’s Monster Hunter Rise: Sunbreak Wins Grand Award and Resident Evil 4 Wins Award for Excellence in the Games of the Year Division at the Japan Game Awards: 2023!25.9.2023 09:00:00 CEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Monster Hunter Rise: Sunbreak was awarded the Grand Award and Resident Evil 4 was awarded an Award for Excellence in the Games of the Year Division of the Japan Game Awards: 2023 (held by the Computer Entertainment Supplier’s Association), while Dragon’s Dogma 2 won an award in the Future Division. The prizes were announced at Tokyo Game Show 2023, which was held from September 21-24. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230925905754/en/ Monster Hunter Rise: Sunbreak is the winner of the Grand Award in the Games of the Year Division at the Japan Game Awards: 2023, and has garnered acclaim for its new locales, monsters, and never-before-experienced hunting actions, while boasting sales of over 6.1 million units worldwide (as of June 30, 2023). (Graphic: Business Wire) Winner of the Grand Award, Monster Hunter Rise: Sunbreak is a massive premium expansion for Monster